Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Apr;6(4):175-83; quiz 184-5.
doi: 10.1111/j.1524-6175.2004.03146.x.

Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study

Takao Saruta  1 , Shigeru Kageyama, Toshio Ogihara, Kunio Hiwada, Masayo Ogawa, Kazuji Tawara, Marjorie Gatlin, Susan Garthwaite, Richard Bittman, Jeffrey Patrick
Affiliations
Clinical Trial

Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study

Takao Saruta et al. J Clin Hypertens (Greenwich). 2004 Apr.

Abstract

Approximately 40% of Japanese patients with essential hypertension, including low-renin hypertension, are inadequately managed. Low-renin hypertension generally responds poorly to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers, but may respond more optimally to diuretics, calcium channel blockers, and aldosterone blockers. This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study evaluated the efficacy and safety of the selective aldosterone blocker eplerenone in 193 Japanese patients with essential hypertension. Although not a study inclusion criterion, baseline active plasma renin levels were consistently low (5.7-10.1 mU/L); most patients met the criteria for low-renin hypertension (< or =42.5 mU/L; normal range, 7-76 mU/L). Patients received placebo or eplerenone 50, 100, or 200 mg once daily for 8 weeks. Systolic blood pressure decreased significantly (-6.8 to -10.6 mm Hg vs. -2.1 mm Hg; p< or =0.0022 vs. placebo). Eplerenone offers significant blood pressure reduction with good tolerability in Japanese patients with hypertension, including those with low-renin hypertension.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Adjusted mean change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline to Week 8
Figure 2
Figure 2
Adjusted mean change in 24‐hour ambulatory systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline to Week 8
Figure 3
Figure 3
Adjusted mean percent change in renin‐angiotensin‐aldosterone system hormone profile from baseline to Week 8
See this image and copyright information in PMC

References

    1. MacFadyen RJ, Lee AF, Morton JJ, et al. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart. 1999;82:57–61. - PMC - PubMed
    1. McKelvie R, Yusuf S, Pericak D, et al. Comparison of candesartan, enalApril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation. 1999;100:1056–1064. - PubMed
    1. Swedberg K, Eneroth P, Kjekshus J, et al., for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82:1730–1736. - PubMed
    1. Stier CT Jr, Chander PN, Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev. 2002;10:97–107. - PubMed
    1. Frierdich G, Schuh J, Brown M, et al. Effects of the selective mineralocorticoid receptor antagonist, eplerenone, in a model of aldosterone‐induced hypertension and cardiac fibrosis [abstract B004]. Am J Hypertens. 1998;11:94A.

Publication types